See more : PhaseRx, Inc. (PZRXQ) Income Statement Analysis – Financial Results
Complete financial analysis of Atossa Therapeutics, Inc. (ATOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Atossa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Southwestern Energy Company (SWN) Income Statement Analysis – Financial Results
- Nippon Building Fund Incorporation (8951.T) Income Statement Analysis – Financial Results
- SK Telecom Co.,Ltd (SKMD.IL) Income Statement Analysis – Financial Results
- EOS, Inc. (EOSS) Income Statement Analysis – Financial Results
- Enel Américas S.A. (ENIAY) Income Statement Analysis – Financial Results
Atossa Therapeutics, Inc. (ATOS)
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.76K | 525.95K | 632.56K | 481.84K | 1.50K | 0.00 | 0.00 |
| Cost of Revenue | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 132.41K | 340.66K | 495.47K | 65.63K | 97.19K | 0.00 | 0.00 |
| Gross Profit | -23.00K | -8.00K | -23.00K | -46.60K | -52.79K | -44.20K | -128.99K | -303.48K | -130.65K | 185.30K | 137.09K | 416.21K | -95.69K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,431.91% | 35.23% | 21.67% | 86.38% | -6,379.33% | 0.00% | 0.00% |
| Research & Development | 17.33M | 15.08M | 9.21M | 6.61M | 6.65M | 4.21M | 2.33M | 770.43K | 2.36M | 2.58M | 1.11M | 1.97K | 0.00 | 120.00K | 21.25K |
| General & Administrative | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 8.85M | 8.63M | 8.56M | 5.02M | 3.17M | 882.16K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42M | 1.27M | 1.26M | 466.82K | 160.85K | 12.20K | 0.00 |
| SG&A | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 10.27M | 9.90M | 9.82M | 5.49M | 3.33M | 894.36K | 101.61K |
| Other Expenses | 0.00 | -146.00K | -85.00K | 50.80K | 25.65K | 29.30K | 154.00 | 718.97K | 0.00 | 2.01M | 0.00 | 0.00 | 0.00 | 63.64K | 0.00 |
| Operating Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.63M | 12.48M | 10.92M | 5.49M | 3.33M | 1.08M | 122.86K |
| Cost & Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.76M | 12.82M | 11.42M | 5.55M | 3.43M | 1.08M | 122.86K |
| Interest Income | 4.34M | 877.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 260.00 | 295.00 | 1.22K | 4.91K | 455.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.82K | 0.00 | 0.00 | 15.77K | 360.00 | 12.04K | 17.99K | 9.14K | 0.00 |
| Depreciation & Amortization | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 272.63K | 564.46K | 472.93K | 130.55K | 15.62K | 455.00 | 0.00 |
| EBITDA | -31.35M | -27.68M | -20.50M | -14.56M | -17.21M | -11.39M | -7.80M | -6.37M | -12.49M | -9.35M | -10.31M | -4.94M | -3.41M | -1.09M | -122.86K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -710,262.91% | -2,336.62% | -1,630.11% | -1,024.66% | -227,243.60% | 0.00% | 0.00% |
| Operating Income | -31.38M | -27.69M | -20.52M | -14.61M | -17.27M | -11.43M | -7.65M | -7.97M | -12.76M | -14.64M | -10.78M | -5.07M | -3.43M | -1.08M | -122.86K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,746.19% | -2,783.97% | -1,704.93% | -1,052.01% | -228,612.67% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.28M | 731.00K | -85.00K | -3.22M | 25.65K | 29.30K | -473.41K | 0.00 | 431.00 | -2.49M | -65.00 | -10.82K | -13.08K | -8.68K | 0.00 |
| Income Before Tax | -30.09M | -26.96M | -20.61M | -17.83M | -17.24M | -11.40M | -8.12M | -6.37M | -12.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,721.67% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -731.00K | -213.56K | 3.27M | -119.07K | -29.30K | 742.46K | -1.76M | 3.00M | 2.35M | 65.00 | 10.82K | 13.08K | 250.00 | 0.00 |
| Net Income | -30.09M | -26.23M | -20.61M | -21.10M | -17.24M | -11.40M | -8.12M | -6.37M | -15.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -896,491.64% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
| EPS | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.96 | -2.42 |
| EPS Diluted | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.58 | -2.42 |
| Weighted Avg Shares Out | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 32.98K | 50.77K |
| Weighted Avg Shares Out (Dil) | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 33.36K | 50.77K |
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating...
Atossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestones
Atossa Therapeutics Inc (NASDAQ:ATOS) told investors it ended 2023 with $88.5 million in cash and cash equivalents and no debt as it advanced its investigational therapeutic (Z)-endoxifen, which is targeting breast cancer and other breast conditions. For the year ended...
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent Company developments. Atossa...
Atossa Therapeutics' breast cancer drug milestone sparks investor enthusiasm
Atossa Therapeutics Inc (NASDAQ:ATOS) shares continued to move higher on Wednesday, buoyed by the news that a patient with pre-menopausal breast cancer had successfully completed a five-year treatment using its investigative breast cancer therapy (Z)-endoxifen. Shares of the biotechnology company...
Atossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifen
Atossa Therapeutics Inc (NASDAQ:ATOS), a company specializing in developing pharmaceuticals, has announced that a pre-menopausal breast cancer patient has completed a successful five-year treatment using its drug (Z)-endoxifen. The Seattle-based company reported that the patient, diagnosed with Estrogen Receptor positive...
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patient who received neoadjuvant...
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)...
Atossa Therapeutics adds breast cancer expert to board
Atossa Therapeutics Inc (NASDAQ:ATOS), the biopharmaceutical company, has appointed Tessa Cigler, the breast cancer specialist, to its board of directors, effective immediately. Cigler works as a medical oncologist and clinical investigator at New York's Weill Cornell Breast Center, dealing with...
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today...
Atossa Therapeutics to present data from ongoing Phase 2 breast cancer trial
Atossa Therapeutics Inc (NASDAQ:ATOS) announced it will present data from the 40mg pharmacokinetic run-in cohort of its ongoing Phase 2 EVANGELINE study at the American Association for Cancer Research Annual Meeting being held in San Diego, California, from April 5 to...
Source: https://incomestatements.info
Category: Stock Reports